healthcaredive - At HIMSS 2026, AWS took the stage with Jupiter Medical Center and Rady Children's Health. Read the key lessons from last week's Views from the Top Session.
#healthcare #digitalhealth #hospitaloperations #healthcarefinance #cybersecurity
Monday, March 16, 2026, 4:21 am / permalink 20798 / 11 stories in 14 hrs
esmo - Findings from the ZSAB-neoGOLP study
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #clinicaltrials
Monday, March 16, 2026, 3:21 am / permalink 20797 / 3 stories in 15 hrs
medicalxpress - In a large, randomized trial, researchers at Mass General Brigham found that high-dose vitamin D3 did not reduce COVID-19 infection severity, but may impact long COVID outcomes. Results of the study are published in The Journal of Nutrition.
#healthcare #publichealth #infectiousdisease #longcovid #clinicaltrials #nutrition #vitamind #supplements
Monday, March 16, 2026, 1:22 am / permalink 20790 / 2 stories in 17 hrs
oncodaily - A major international clinical trial, NRG-LU005, has provided important new insight into how immunotherapy should be used in limited-stage small cell lung cancer (SCLC). While immune checkpoint inhibitors have significantly […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Monday, March 16, 2026, 12:23 am / permalink 20789 / 4 stories in 18 hrs
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook 11 stories in 14.7 hours
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma 3 stories in 15.7 hours
Vitamin D trial shows reduced long‑COVID risk but no severity benefit 2 stories in 17.7 hours
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival 4 stories in 18.7 hours
FDA approves leucovorin for rare folate disorder despite autism hype 4 stories in 30.7 hours
HORMAD1 emerges as a potential target in triple‑negative breast cancer 4 stories in 43.7 hours
Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio 2 stories in 46.7 hours
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial 5 stories in 47.7 hours
Novo Nordisk and Hims bury the hatchet and carve a deal 3 stories in 52.7 hours
AI improves UK breast-screening detection by about 10% 5 stories in 52.7 hours
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.
Bluesky: